Amedisys (NASDAQ:AMED) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Amedisys (NASDAQ:AMED – Get Free Report) in a report issued on Sunday. The brokerage set a “buy” rating on the health services provider’s stock.

Separately, Cantor Fitzgerald upped their target price on shares of Amedisys from $100.00 to $101.00 and gave the stock a “neutral” rating in a research report on Thursday, September 14th. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $103.55.

Check Out Our Latest Analysis on Amedisys

Amedisys Price Performance

Shares of Amedisys stock opened at $93.70 on Friday. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of 1,338.76, a P/E/G ratio of 2.56 and a beta of 0.92. Amedisys has a 1-year low of $69.36 and a 1-year high of $106.01. The firm’s 50-day moving average price is $92.96 and its two-hundred day moving average price is $91.54.

Amedisys (NASDAQ:AMED – Get Free Report) last issued its quarterly earnings data on Tuesday, October 24th. The health services provider reported $0.98 earnings per share for the quarter, missing the consensus estimate of $1.08 by ($0.10). The firm had revenue of $556.24 million for the quarter, compared to the consensus estimate of $560.23 million. Amedisys had a return on equity of 13.45% and a net margin of 0.12%. Amedisys’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.15 earnings per share. On average, equities analysts predict that Amedisys will post 4.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amedisys

Several large investors have recently bought and sold shares of AMED. Pinebridge Investments L.P. bought a new stake in Amedisys in the second quarter valued at approximately $26,000. Neo Ivy Capital Management bought a new stake in Amedisys in the second quarter valued at approximately $44,000. Headlands Technologies LLC bought a new stake in Amedisys in the second quarter valued at approximately $46,000. Covestor Ltd increased its stake in Amedisys by 88.9% in the first quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock valued at $56,000 after purchasing an additional 152 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Amedisys in the first quarter valued at approximately $67,000. Institutional investors own 95.70% of the company’s stock.

Amedisys Company Profile (Get Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

You may also like

PDD (NASDAQ:PDD) Price Target Raised to $190.00 at Benchmark

The Bank of Nova Scotia (NYSE:BNS) Plans $0.78 Quarterly Dividend

O’Reilly Automotive, Inc. (NASDAQ:ORLY) Director Dana Perlman Sells 100 Shares